The BIO CEO Investor Conference remains one of the most important events for companies, investors and industry executives to explore partnerships, raise capital, network or simply gain some useful, fresh insight from industry experts. Monday’s opening Plenary Session, Word on the Street–Buy Side View for 2013, was informative and featured some of the industry’s most respected names.
ALLERGY is a burgeoning disease, and food allergies represent the segment where life can be directly threatened. In the U.S., more than three million people are allergic to peanut. Indeed, peanut allergy causes about 100 to 150 deaths each year in the U.S.—but no treatment is currently available. Until now, avoidance of the culprit food has been the primary solution.
Aftab Jamil of BDO spoke with OneMedTV during the 6th Annual OneMedForum in January to discuss the state of life sciences investment, and how companies can formulate new strategies to attract a sustainable class of investors. At the core of these new strategies are the initiatives being implemented to increase access to non-venture capital in the earlier rounds, which may incubate a company long enough to grow a pipeline, attract tenable/diverse revenue opportunity, and eventually reach market.
Last month, Santarus, Inc’s Uceris for ulcerative colitis received FDA approval, and the company has announced a planned launch in March 2013. Santaurs has already begun adding 85 new positions to its sales staff in anticipation of Uceris’ future. The Uceris approval hopes to promise strong returns for a company with a checkered past, but a promising future.
Aside from re-defined financing structures, the most important issue facing life sciences EGCs is the need to increase clinical trial efficiency and productivity so that development budgets are used prudently to support products that have the best chance of market success. Speaking to OneMedTV during OneMedForum this past January, Donnelly discussed current changes that will impact the future of product development and the central role that innovative trial design will play in this.
The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in […]
As part of our ongoing efforts to introduce our readers to intriguing investment opportunities, OneMedPlace has published an update of Amarantus Bioscience (AMBS). In our […]
“On my second trip to Uganda in 2005 I operated on a 15-year-old girl who had fallen out of a mango tree and broke her neck. She was essentially a paraplegic,” recalls Dr. Isador “Izzy” Lieberman, a spine surgeon with Texas Back Institute.
Response Biomedical Corp. (RBM.TO)(RPBIF) is bringing in 2013 with a bang announcing their 2nd US distribution deal since the 1st week in January. Earlier in the month Response Biomedical entered a distribution agreement with US hospital supplier Laboratory Supply Company Inc. (Labsco) to distribute its cardiovascular portfolio of RAMP® products to small hospitals. By the end of January Response Biomedical announced their 2nd US distribution agreement with Fishers Healthcare for their RAMP® Flu A + B tests and RAMP® RSV test on the RAMP® 200.
Vascular Nanotransfer Technologies (VNT) says it has developed the industry’s most versatile Drug-Coated-Balloon (DCB) platform designed to deliver a wide variety of drugs for best-in-class DCB applications.
Copyright © 2024 | WordPress Theme by MH Themes